Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Mass deworming experiment aims to wipe out parasitic worms in three countries

NCT ID NCT03014167

First seen Jan 31, 2026 · Last updated Jun 20, 2026 · Updated 19 times

Summary

This massive study tested whether giving deworming medicine (albendazole) to everyone in a community, not just children, can break the cycle of soil-transmitted worm infections. Over 350,000 people in India, Malawi, and Benin took part. The goal was to see if treating entire villages for three years could reduce infections to very low levels and keep them there.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HELMINTHIASIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Christian Medical College

    Vellore, India

  • Institut de Recherche pour le Développement

    Comé, Benin

  • London School of Hygiene and Tropical Medicine

    Mangochi, Malawi

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Albendazole (a deworming drug)

What this could lead to

If successful, this could show that treating entire communities with deworming medicine can stop the spread of soil-transmitted worms, leading to simpler and more effective public health programs.

What could go wrong

The trial is very large but results may vary by region. Even if transmission drops, worms could return if treatment stops. Also, the drug is not given to pregnant women in early pregnancy or very young children, which could limit impact.

Conditions

The condition(s) this trial relates to.

filariasis helminthiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.